Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology …
Over the last 12 months, insiders at Champions Oncology, Inc. have bought $95,972 and sold $0 worth of Champions Oncology, Inc. stock.
On average, over the past 5 years, insiders at Champions Oncology, Inc. have bought $166,483 and sold $5.31M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mendelson Daniel Newman (director) — $95,972.
The last purchase of 1,000 shares for transaction amount of $6,500 was made by Mendelson Daniel Newman (director) on 2024‑01‑12.
2024-01-12 | director | 1,000 0.0071% | $6.50 | $6,500 | -27.48% | |||
2024-01-11 | director | 2,000 0.0147% | $6.27 | $12,540 | -22.45% | |||
2024-01-10 | director | 2,944 0.022% | $6.31 | $18,577 | -21.69% | |||
2024-01-09 | director | 3,000 0.0221% | $6.25 | $18,750 | -21.79% | |||
2024-01-08 | director | 1,000 0.0074% | $6.15 | $6,150 | -21.10% | |||
2024-01-05 | director | 2,000 0.0146% | $6.09 | $12,180 | -20.10% | |||
2024-01-04 | director | 3,000 0.0221% | $6.12 | $18,360 | -19.75% | |||
2024-01-03 | director | 500 0.0035% | $5.83 | $2,915 | -20.20% | |||
2023-12-21 | director | 2,500 0.0184% | $4.92 | $12,300 | -0.10% | |||
2023-12-20 | director | 2,100 0.015% | $4.82 | $10,122 | -1.01% | |||
2023-12-19 | director | 5,000 0.0384% | $4.75 | $23,750 | +4.46% | |||
2023-10-11 | director | 5,000 0.0385% | $6.40 | $32,000 | -18.15% | |||
2023-10-10 | director | 1,100 0.008% | $6.41 | $7,051 | -20.97% | |||
2023-10-06 | director | 1,530 0.0114% | $6.48 | $9,914 | -21.47% | |||
2023-10-05 | director | 2,000 0.0156% | $6.47 | $12,940 | -18.23% | |||
2023-10-04 | director | 5,000 0.0386% | $6.40 | $32,000 | -19.52% | |||
2023-10-03 | director | 2,500 0.019% | $6.30 | $15,750 | -19.27% | |||
2023-09-29 | director | 4,000 0.0294% | $6.16 | $24,640 | -17.71% | |||
2023-09-28 | director | 5,000 0.0379% | $6.22 | $31,100 | -15.63% | |||
2023-09-27 | director | 1,500 0.0115% | $5.95 | $8,925 | -11.16% |
Mendelson Daniel Newman | director | 198625 1.4373% | $8.14 | 30 | 2 | +54.24% |
BROWN MICHAEL MAURICE | 10 percent owner | 22281040 161.2325% | $8.14 | 2 | 0 | |
Battery Ventures IX, L.P. | 10 percent owner | 22281040 161.2325% | $8.14 | 2 | 0 | |
ACKERMAN JOEL | director | 1021731 7.3936% | $8.14 | 10 | 1 | +66.02% |
Morris Ronnie | CEO | 858878 6.2151% | $8.14 | 16 | 1 | +86.37% |
Battery Management Corp | $11.87M | 17.82 | 2.42M | 0% | +$0 | 2.62 | |
Nea Management Company Llc | $8.4M | 12.61 | 1.71M | 0% | +$0 | 0.04 | |
Tocqueville Asset Management | $3.35M | 5.04 | 684,628 | +<0.01% | +$245.00 | 0.05 | |
Renaissance Technologies | $611,000.00 | 0.92 | 124,691 | -0.08% | -$490.01 | <0.01 | |
BlackRock | $566,847.00 | 0.85 | 115,683 | -0.36% | -$2,028.60 | <0.0001 |